RAPT THERAPEUTICS, INC. (RAPT): Price and Financial Metrics


RAPT THERAPEUTICS, INC. (RAPT): $13.44

0.17 (+1.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RAPT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RAPT POWR Grades


  • Sentiment is the dimension where RAPT ranks best; there it ranks ahead of 73.43% of US stocks.
  • The strongest trend for RAPT is in Value, which has been heading down over the past 179 days.
  • RAPT's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

RAPT Stock Summary

  • The ratio of debt to operating expenses for RAPT Therapeutics Inc is higher than it is for about merely 0.5% of US stocks.
  • RAPT's price/sales ratio is 176.68; that's higher than the P/S ratio of 98.46% of US stocks.
  • As for revenue growth, note that RAPT's revenue has grown -24.38% over the past 12 months; that beats the revenue growth of only 6.33% of US companies in our set.
  • Stocks that are quantitatively similar to RAPT, based on their financial statements, market capitalization, and price volatility, are RNA, FGEN, ARCT, KLDO, and ATRA.
  • RAPT's SEC filings can be seen here. And to visit RAPT Therapeutics Inc's official web site, go to www.rapt.com.

RAPT Valuation Summary

  • RAPT's price/sales ratio is 196; this is 5057.89% higher than that of the median Healthcare stock.
  • Over the past 22 months, RAPT's EV/EBIT ratio has gone down 9.1.
  • RAPT's price/sales ratio has moved NA NA over the prior 22 months.

Below are key valuation metrics over time for RAPT.

Stock Date P/S P/B P/E EV/EBIT
RAPT 2021-08-31 196.0 4.4 -16.1 -14.8
RAPT 2021-08-30 192.3 4.3 -15.8 -14.5
RAPT 2021-08-27 191.7 4.3 -15.7 -14.4
RAPT 2021-08-26 192.8 4.4 -15.8 -14.5
RAPT 2021-08-25 193.1 4.4 -15.8 -14.5
RAPT 2021-08-24 191.3 4.3 -15.7 -14.4

RAPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RAPT has a Quality Grade of D, ranking ahead of 15.97% of graded US stocks.
  • RAPT's asset turnover comes in at 0.034 -- ranking 343rd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RAPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.034 1 -0.626
2021-03-31 0.043 1 -0.647
2020-12-31 0.037 1 -0.651
2020-09-30 0.030 1 -0.885
2020-06-30 0.020 1 -1.302
2019-12-31 0.000 NA 97.551

RAPT Price Target

For more insight on analysts targets of RAPT, see our RAPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $62.14 Average Broker Recommendation 1.43 (Moderate Buy)

RAPT Stock Price Chart Interactive Chart >

Price chart for RAPT

RAPT Price/Volume Stats

Current price $13.44 52-week high $43.26
Prev. close $13.27 52-week low $9.85
Day low $12.67 Volume 209,000
Day high $13.95 Avg. volume 301,654
50-day MA $18.78 Dividend yield N/A
200-day MA $27.63 Market Cap 398.42M

RAPT THERAPEUTICS, INC. (RAPT) Company Bio


Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.


RAPT Latest News Stream


Event/Time News Detail
Loading, please wait...

RAPT Latest Social Stream


Loading social stream, please wait...

View Full RAPT Social Stream

Latest RAPT News From Around the Web

Below are the latest news stories about RAPT Therapeutics Inc that investors may wish to consider to help them evaluate RAPT as an investment opportunity.

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Healthcare Conference on Wedne

Yahoo | February 9, 2022

State Board Of Administration Of Florida Retiremen Buys Canadian Pacific Railway, VMware Inc, ...

Investment company State Board Of Administration Of Florida Retiremen (Current Portfolio) buys Canadian Pacific Railway, VMware Inc, Coterra Energy Inc, Realty Income Corp, Clarivate PLC, sells , , , , during the 3-months ended 2021Q4, according to the most recent filings of the investment company, State Board Of Administration Of Florida Retiremen.

Yahoo | February 8, 2022

RAPT crashes ahead of presentation at J.P. Morgan Conference (NASDAQ:RAPT)

RAPT Therapeutics <> has recorded its biggest intraday loss since November 2020 on below-average volume as the clinical-stage biotech prepares for a presentation at a major…

Seeking Alpha | January 10, 2022

RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:00 a.

Yahoo | January 4, 2022

Read More 'RAPT' Stories Here

RAPT Price Returns

1-mo -33.20%
3-mo -32.46%
6-mo -61.60%
1-year -39.02%
3-year N/A
5-year N/A
YTD -63.41%
2021 85.97%
2020 -28.47%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.6532 seconds.